Wegovy Costs Across Federal Programs, Compared

Last updated 19 hours ago. Our resources are updated regularly but please keep in mind that links, programs, policies, and contact information do change.

A patient can find a lower Wegovy copay in another government health program and still be unable to use that price. Each copay, the patient’s fixed charge, belongs to a covered benefit with its own eligibility and prescription-coverage rules.

Medicare’s prescription-drug coverage (Part D), Medicaid and other programs may give the same prescription different answers: coverage, an approval requirement, or no coverage. A cash offer adds a price paid without insurance.

Patient charges and spending credit, compared

A deductible is the amount paid for covered services before a plan’s deductible-based coverage begins; some benefits can be paid before it is met. A formulary is a plan’s list of covered prescription drugs.

Prior authorization is the plan’s advance decision that a prescription is medically necessary; it does not guarantee payment.

For VA and TRICARE, confirm coverage and the exact product’s tier before treating the published tier rate as a Wegovy quote. Active-duty TRICARE members pay nothing for covered drugs at military pharmacies, home delivery or retail network pharmacies. The main TRICARE rate table excludes medically retired sponsors and certain survivors and shows zero-cost Prime Remote exceptions.

Medicare has three different pricing questions

Wegovy is a glucagon-like peptide-1 (GLP-1) drug. Wegovy injections have FDA-labeled weight-management and cardiovascular-risk-reduction uses, with different eligibility conditions. Wegovy tablets have adult weight-management and cardiovascular-risk-reduction indications. A price or coverage rule for one form and use should not be assumed to cover the other.

Ordinary Medicare Part D excludes drugs when used for weight loss, even when obesity is not a cosmetic concern. A Wegovy prescription to reduce major cardiovascular risks in an adult with established cardiovascular disease and obesity or overweight is a Part D-coverable example identified by the Centers for Medicare & Medicaid Services (CMS). A prescription for a Part D-coverable use must follow the plan’s coverage or formulary-exception process, even if the drug is absent from its formulary, rather than shifting to the Bridge.

Standalone Medicare drug plans require Part A or Part B; Medicare Advantage requires both. No Part D plan may have a deductible above $615 in 2026 or $700 in 2027. After the annual covered-drug spending limit is reached, the patient owes nothing for covered Part D drugs for the rest of the calendar year. Extra Help assists people with limited income and resources with Part D premiums, deductibles, coinsurance and other costs.

The Medicare GLP-1 Bridge runs from July 1, 2026 through December 31, 2027 outside the Part D benefit. Access requires enrollment in an eligible Medicare Part D drug plan even though the payments sit outside that benefit. It includes Wegovy injection and tablets. Its $50 monthly copay cannot be reduced through Extra Help. The Bridge therefore offers access to a separate benefit rather than a new Part D formulary entry.

Ask the prescriber to check Bridge eligibility at the start of treatment. The adult patient must use the drug for weight reduction or maintenance with ongoing nutrition and physical-activity changes. The qualifying clinical paths are:

• Age 18 or older with a body mass index (BMI) of at least 35 when treatment begins.
• Age 18 or older with BMI of at least 30 and heart failure with preserved ejection fraction, uncontrolled hypertension or chronic kidney disease stage 3a or above.
• Age 18 or older with BMI of at least 27 and prediabetes, a previous heart attack, a previous stroke or symptomatic peripheral artery disease, meaning blocked arteries in the legs or arms with symptoms.

For this program, uncontrolled hypertension means systolic pressure above 140 or diastolic pressure above 90 despite treatment with two blood-pressure medications. Meeting a BMI path does not override the requirement to use ordinary Part D for a Part D-coverable prescription.

CMS excludes beneficiaries with type 2 diabetes, moderate-to-severe obstructive sleep apnea, or qualifying noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH), even if they meet the Bridge’s weight criteria. MASH is a liver disease in which fat buildup causes inflammation and scarring; noncirrhotic refers to disease without cirrhosis, or severe liver scarring. Ask the prescriber to confirm the relevant diagnoses and the prescription’s purpose.

The provider sends the prescription to the pharmacy, completes prior authorization when requested and certifies participation in a diet-and-exercise lifestyle program. Approved authorization covers refills and dose changes through December 31, 2027 unless the patient switches drugs.

The negotiated Medicare agreement specifies an effective date of January 1, 2027. CMS lists $274 for a 30-day equivalent supply for the combined Ozempic, Rybelsus and Wegovy grouping. Its package-level example for four Wegovy 2.4 mg/0.75 mL pens is $385.63. Neither figure is a promise that a patient’s pharmacy copay will be that amount.

CMS says the Medicare component of BALANCE, its broader access model, is not launching in 2027; the Bridge has instead been extended through December 31, 2027. A negotiated drug price, a temporary access benefit and an individual Part D copay answer different questions.

Medicaid coverage depends on the state and the medical use

Federal Medicaid rules allow states to restrict or exclude drugs when used for weight loss. California’s Medi-Cal Rx program stopped covering weight-loss-only Wegovy on January 1, 2026, but continues coverage for noncirrhotic MASH with a diagnosis code and directs cardiovascular-disease users to seek prior authorization. Check your state’s current preferred-drug list and the rules for the diagnosis on the prescription.

For nonpreferred drugs, states may charge up to 20 percent of the drug cost when income exceeds 150 percent of the federal poverty level; at or below that level, copays are limited to nominal amounts. States choose preferred-drug categories and may vary charges by mail-order or retail pharmacy. Those federal limits cannot supply a nationwide Wegovy copay or establish coverage of an excluded prescription.

Low-income families, qualified pregnant women and children, and people receiving Supplemental Security Income are examples of mandatory Medicaid eligibility groups; states can cover additional groups. The state Medicaid agency handles applications, eligibility questions, claims and provider contacts. Use the state contact list to check both enrollment eligibility and the current Wegovy authorization route.

CMS’s published BALANCE status was checked on September 30, 2026. BALANCE also has a voluntary Medicaid route: state agencies can apply to join beginning in May 2026 through January 1, 2027. That state-by-state participation is separate from the unlaunched Medicare component. Ask the state Medicaid agency whether it participates and which coverage and authorization rules apply.

VA and TRICARE separate enrollment from drug approval

VA says qualifying active military, naval or air service without a dishonorable discharge may establish health-care eligibility. Check VA’s eligibility page for the full service and enrollment rules. VA prescriptions must be written or approved by a VA doctor.

VA’s weight-management criteria address both Wegovy injection and oral tablets. They require documented comprehensive lifestyle intervention covering diet, physical activity and behavioral changes, plus BMI of at least 27 with a weight-related comorbidity. Individual exceptions are adjudicated under the local facility’s pharmacy-committee and pharmacy-service policies.

VA’s active-product copay list places weight-loss semaglutide pen and tablet products in tier 3. A copay-tier listing does not establish that an individual prescription will be authorized. Ask the VA pharmacy to verify the exact product’s current National Formulary status and applicable criteria. Priority group 1 veterans owe no medication copay. Veterans in priority groups 2 through 8 may owe copays for prescriptions treating non-service-connected conditions, meaning conditions unrelated to military service. Confirm whether a VA exemption applies before using the tier-3 amounts.

A Federal Supply Schedule price is a negotiated purchasing-contract price available to eligible federal agencies. VA’s Contract Catalog Search Tool lists contract pricing and ordering information. This comparison does not provide a verified Wegovy-specific Federal Supply Schedule package quote; use the contract catalog for a purchasing price. The purchasing price should not be treated as the veteran’s pharmacy bill.

A military sponsor’s uniformed service determines TRICARE eligibility and reports it through the Defense Enrollment Eligibility Reporting System (DEERS); eligible spouses and children must be registered there. For weight management, TRICARE lists coverage under Prime, Prime Remote, US Family Health Plan, Select, Young Adult, Reserve Select, Retired Reserve and the Continued Health Care Benefit Program. It requires clinical eligibility, a network-provider prescription and prior authorization.

TRICARE excludes weight-loss drugs for TRICARE For Life and direct-care-only beneficiaries and certain other groups, even with an approved prior authorization. Use the current TRICARE Formulary Search for the exact form, dose, tier and authorization forms; ask the pharmacy to confirm the final bill. The plan, beneficiary group and pharmacy type determine whether a deductible applies before prescription copays or cost sharing. Payments for noncovered services do not count toward TRICARE’s catastrophic cap.

FEHB and Marketplace plans require a plan-specific check

Eligible federal employees and family members can enroll in FEHB unless the employee’s position is excluded; continuing coverage in retirement has separate requirements. The Office of Personnel Management (OPM) prohibits a blanket anti-obesity-medication exclusion and requires at least one weight-loss drug from this class and two additional oral anti-obesity options. That class requirement does not guarantee Wegovy on every FEHB formulary.

OPM requires carriers’ drug cost calculators to show pricing, utilization-management restrictions, deductible and out-of-pocket accumulators (credited spending), supply limits and pharmacy-network prices. Choose the actual plan and option, enter the exact Wegovy product and pharmacy, and read the brochure’s prescription section.

For example, MHBP Standard Option combines eligible covered network medical and prescription expenses toward a $6,000 Self Only or $12,000 family annual limit. This is an example of a plan’s protection, not a universal FEHB limit or a Wegovy price.

Marketplace enrollment generally requires U.S. residence, citizenship or lawful presence, and no incarceration; people with Medicare cannot enroll in a Marketplace health or dental plan. HealthCare.gov directs enrollees to the insurer’s covered-drug list, Summary of Benefits and Coverage, or insurer contact information to check prescriptions. Check the exact dosage form before selecting a plan or filling the prescription.

When a prescription exception is approved, a Marketplace plan generally charges its highest covered-drug copay and counts the payment toward the deductible and/or out-of-pocket limit. The exception’s cost and spending credit can therefore differ from buying the same medicine with a cash offer.

TrumpRx offers cash prices for both pen and pill

The cash prices and eligibility statements in this comparison were checked on September 30, 2026.

The TrumpRx pen coupon requires a valid prescription, self-payment, age 18 or older and U.S. or territory residency; the coupon is presented at the pharmacy. The $199 introductory pen price applies to two monthly fills at 0.25 mg or 0.5 mg through December 31, 2026. Later fills cost $349 monthly at 0.25, 0.5, 1, 1.7 or 2.4 mg, or $399 at the HD 7.2 mg dose.

The manufacturer’s pill offer defines a month as a bottle of 30 tablets and prices it by dose. It reserves the right to modify or cancel the offer. Compare the prescribed dose with the pill amounts in the table rather than assuming the lowest introductory dose price continues at a higher dose.

NovoCare’s terms say government-program enrollees can pay the self-pay price outside insurance. The TrumpRx pill page nevertheless says “Government beneficiaries excluded.” These eligibility statements conflict. Ask the dispensing pharmacy or manufacturer to confirm the terms it will honor before relying on the offer.

The manufacturer does not classify FEHB, Marketplace or state-employee insurance as government health programs for this offer. The cash purchase cannot be submitted for insurance reimbursement or counted toward its deductible or out-of-pocket limit. Compare the cash bill with the covered bill and the credit each earns toward the year’s remaining limit.

Get a coverage decision before choosing cash

Ask the pharmacy for two clearly labeled quotes: the insured charge after any deductible and authorization, and the cash-offer charge for the same form, dose and supply. Ask which payment will be credited to the plan’s annual limit.

An FEHB denial follows the brochure’s disputed-claims route: plan reconsideration first, then OPM review if the member still disagrees. Medicaid’s written notice must explain how to request a fair hearing and the request deadline. Follow the notice rather than assuming every program uses the same appeal period.

For a Marketplace drug exception, the doctor can explain why covered alternatives are ineffective or harmful, or why the allowed quantity will not work. A denied exception can be appealed and reviewed by an independent third party. For Medicare or TRICARE, ask the plan or pharmacy which coverage or authorization process applies to the denial.

The lowest cash number can be useful, but only a comparison for the actual prescription reveals what the purchase costs now and what protection remains later in the year.

For related explainers, browse the GovFacts prescription-drug collection.